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Identity 
Other names: E2F-3; KIAA0075; Y10479 
HGNC (Hugo): E2F3 
Location: 6p22.3 
Local order: tel-OACT1-E2F3-CDKAL1-cen. 
DNA/RNA 
Description 
The gene has 7 exons (two alternative exons 1) and 6 
introns comprising 91545 bp. 
Transcription 
Transcription takes place in a centromeric -> telomeric 
orientation. The length of the processed  
mRNA is about 4744 bp. EMBL lists two alternativly 





E2F3A comprises 465 amino acid residues (49 kDa), 







Schematic diagram of the E2F3 gene comprising 7 exons (in blue). Exons 1a or 1b are used alternatively to produce variants E2F3A or 
E2F3B, respectively. The sizes in base pairs (bp) of exons (above) and introns (below) are shown. 
 
Schematic diagram of E2F3 protein structure. E2F3A is shown in the upper part, E2F3B below. The proteins differ in their N-terminal 
regions comprising 132 and 6 amino acid residues, respectively. N: nuclear localization sequence, LZ: leucine zipper (blue), RBD: pRB 
binding domain (light blue). DNA binding domain (yellow), dimerization domain (red), transactivation domain (green). The positions of 
amino acid residues are indicated. 










E2F3 is a sequence-specific transcription factor 
implicated in cell cycle regulation (S-phase). It is a 
transcriptional activator for E2F-responsive genes. E2F 
proteins heterodimerize with DP proteins and are 
subject to inhibition by binding to the pocket domain of 
retinoblastoma protein (pRB). Phosphorylation of pRB 
sets E2F proteins free to regulate their target genes. 
Homology 
E2F transcription factor family consists of E2F-proteins 
(E2F1-6) and DP-proteins (DP1, DP2). 
Mutations 
Note 









Medium-to-high-level genomic amplification 
sometimes resulting in HSR formation and believed to 
target E2F3 which lies within the common amplified 
region (see image below). Genomic amplification may 
not be required for over-expression. 
Disease 
Notably, bladder and prostate cancers. 
Prognosis 
Associated with invasiveness in bladder cancer, and 
with poor survival in prostate cancer. Circa 33% of 
primary transitional cell carcinomas of the bladder 
overexpress nuclear E2F3 protein. 
Cytogenetics 
Presumptive target of genomic amplification at 6p22 in 
bladder cancer where it effects E2F3 overexpression 
(as exemplified by the bladder cancer cell lines 5637 
and HT-1367).  
 
 
Genomic amplification of E2F3: FISH image shows HT-1376 bladder cancer cell line (DSMZ acc 397) hybridized with a BAC clone 
(RPMI-99F1) covering the E2F3 locus at 6p22.3. (See breakpoint diagram below for map.) Note high level genomic amplification 
comprising multiple tandemly repeated copies of E2F3 via formation of an homogeneously staining region (HSR) in a marker 
chromosome - a hallmark of oncogene activity. Similar findings have been reported in both primary bladder and prostate cancers. 
Analysis of E2F3 protein has confirmed overexpression in cell lines evidencing genomic amplification, including HT-1376 as well as 5637 
(DSMZ acc 35) and TCC-SUP (DSMZ acc 377). 
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However, E2F3 may not be the only target gene inside 
the common amplified region. 
Hybrid/Mutated gene 
Not yet reported. 
t(6;9)(p22;p13) 
Note 
Observed in a DLBCL cell line: yet to be described 
clinically. 
Disease 




Breakpoint lies upstream of E2F3 and juxtaposes 
upstream (regulatory) region of PAX5. 
Hybrid/Mutated gene 
Not yet reported. 
Oncogenesis 
E2F3 behaves like a classical oncogene and is subject 
to upregulation via genomic amplification in bladder 
and prostate cancers.  
Upregulated E2F3 stimulates cycle progression and 
proliferation. E2F3 transcription is induced by MYC 
and these together conspire to promote G1/S-phase 
transition.  
This activity is negatively regulated by binding of the 
E2F transactivation domain to RB1 or p107. In prostate 
cancer, oncogenesis directed by E2F3 may be mediated 
by the polycomb group protein Enhancer of Zeste 
Homolog gene 2 (EZH2). E2F3 may also activate 
survivin transcription. In Hodgkin lymphoma which, 
though lacking recurrent chromosomal rearrangements 
at 6p22, shows a pattern of gene dysregulation 
reminiscent of prostate cancer, E2F3 regulates HLXB9 
expression which in turn drives IL-6 expression 
thought to play a central role in this enigmatic tumor. 
E2F3 may also act as a tumor suppressor though the 
supporting evidence is tentative. Thus, while E2F3 loss 
results in centrosome defects associated with 
aneuploidy and promote metastasis of medullary 
thyroid carcinoma, E2F3 -/- mice show no excess 
tumor incidence. Furthermore, loss of E2F3 has been 
associated with suppression of pituitary tumors. 
Breakpoints 
 
Figure depicts location of sole E2F3 breakpoint described hitherto, lying approximately 50-150 Kbp upstream of the transcription unit as 
detected in a complex t(6;9)(p22;p13) in a DLBCL cell line. The upstream region of E2F3 is thus juxtaposed with the upstream regulatory 
region of PAX5. Figure shows genes flanking E2F3 together with RPCI-11 library clones. 
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